MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

Cladribine Tablets Journal Publications

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

COVID-19 Vaccination in Patients with Multiple Sclerosis: What We Have Learnt by February 2021.

Achiron | Mult Scler. 2021 May;27(6):864-870.

Humoral Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Treated with High-Efficacy Disease-Modifying Therapies.

Achiron | Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835.

Effect of Cladribine on COVID-19 Serology Responses Following Two Doses of the BNT162b2 mRNA Vaccine in Patients with Multiple Sclerosis.

Brill | Mult Scler Relat Disord. 2021 Oct 23:103343.

Effect of Cladribine Tablets on Lymphocyte Reduction and Repopulation Dynamics in Patients with Relapsing Multiple Sclerosis.

Comi | Mult Scler Relat Disord. 2019 Apr;29:168-174.

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis.

Cook | Multiple sclerosis and related disorders. 2019 Apr 1;29:157-67.

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS

De Stefano | Neurol Neuroimmunol Neuroinflamm. 2022 Jun 14;9(4):e1187.

Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets.

Giovannoni | Frontiers in Immunology. 2021 Dec 24;12:763433.

Safety and Efficacy of Cladribine Tablets in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized Extension Trial of the CLARITY Study.

Giovannoni | Multiple Sclerosis Journal. 2018, Vol. 24(12) 1594 –1604.

Durability of no Evidence of Disease Activity-3 (NEDA-3) in Patients Receiving Cladribine Tablets: The CLARITY Extension Study.

Giovannoni | Multiple Sclerosis Journal. 2022 Jul;28(8):1219-28.

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.

Giovannoni | Multiple Sclerosis Journal. 2023 May;29(6):719-30.

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis.

Giovannoni | N Engl J Med. 2010; 362: 416-26.

Long-Term Safety Data from the Cladribine Tablets Clinical Development Program in Multiple Sclerosis.

Leist | Mult Scler Relat Disord. 2020 Nov;46:102572.

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

Rammohan | Drugs. 2020 Dec;80(18):1901-1928.

Effects of Cladribine Tablets on Lymphocyte Subsets in Patients with Multiple Sclerosis: An Extended Analysis of Surface Markers.

Stuve | Ther Adv Neurol Disord. 2019 Jun 18;12:1756286419854986.

Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy.

Wiendl | Neurology: Neuroimmunology & Neuroinflammation. 2022 Nov 21;10(1):e200048.

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options:

Cladribine Tablets Journal Publications

Cookie Disclaimer

Welcome to EMD Serono Medical Information!